Open

Coming up

Don't miss

Replay


LATEST SHOWS

ENCORE!

Weekly Music Show: Tony Bennett and Lady Gaga's new album

Read more

AFRICA NEWS

Frenchman kidnapped in Algeria: 'IS'-linked jihadists claim abduction of 55 year-old tourist

Read more

DEBATE

What's the deal with Turkey? (part 2)

Read more

MEDIAWATCH

The Sarkozy soap opera

Read more

DEBATE

What's the deal with Turkey?

Read more

LIFESTYLES

New road trip

Read more

LIFESTYLES

High-tech in France

Read more

DOWN TO EARTH

Global warming: A drowning planet

Read more

THE BUSINESS INTERVIEW

Christian Kastrop, Director of Policy Studies, OECD

Read more

Researchers zero in on Alzheimer's plaque origin

Latest update : 2008-04-09

Researchers have found a key ingredient, produced by a brain cell activity, for the formation of Alzheimer's plaques.

Researchers have found that a key ingredient for the formation of Alzheimer's plaques is produced by a brain cell activity, according to a study that helps understand the disease's origin.

The ability of brain cells to absorb substances from their surface, a process called endocytosis, is essential to producing amyloid beta, a protein fragment that clusters together to form Alzheimer's plaques, said the study released Wednesday.

The researchers found that by giving a drug that blocks endocytosis to a mouse with Alzheimer's disease, levels of amyloid beta sank by 70 percent, according to the study published in the journal Neuron.

But using the drug to treat Alzheimer's is not an option because brain cells need to be able to take in substances from the surface, said the neuroscientists at Washington University School of Medicine in St. Louis.

"Blocking endocytosis isn't a viable option for treatment because cells throughout the body, including brain cells, need endocytosis for healthy function," said the study's first author, John Cirrito, research instructor in neurology.

"But we are starting to understand the origins of amyloid beta in more detail now, and what we're learning is opening other options we can pursue to seek new treatments for Alzheimer's disease," he said.

The researchers believe the brain cells may be accidentally taking in amyloid precursor protein (APP), which breaks down into amyloid beta.

In that case, they said, a drug that reduces APP intake could help reduce production of amyloid beta.
 

Date created : 2008-04-09

COMMENT(S)